Cholinesterase inhibitors and pisa syndrome: A pharmacovigilance study

Pharmacotherapy

Volumn 34, Issue 3, 2014, Pages 272-278

  Zannas, Anthony S ^a   Okuno, Yasushi ^b   Doraiswamy, P Murali ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholinesterase inhibitors; Dystonia; Pisa syndrome; Pleurothotonus

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

AGE DISTRIBUTION; AGED; ALGORITHM; ARTICLE; CAUSAL ATTRIBUTION; DEMENTIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PISA SYNDROME; RETROSPECTIVE STUDY; SEX RATIO;

CHOLINESTERASE INHIBITORS; DYSTONIA; PISA SYNDROME; PLEUROTHOTONUS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; DYSTONIA; FEMALE; HUMANS; MALE; PHARMACOVIGILANCE;

EID: 84898044337     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1359     Document Type: Article

References (26)

1. Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972;202: 94-103.
2. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs 2002;16: 165-74. (Pubitemid 34280600)
3. Stübner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry 2000;61: 569-74.
4. Yassa R, Nastase C, Cvejic J, Laberge G. The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry 1991;29: 942-5.
5. Kim JS, Park JW, Chung SW, Kim YI, Kim HT, Lee KS. Pisa syndrome as a motor complication of Parkinson's disease. Parkinsonism Relat Disord 2007;13: 126-8.
6. Patel S, Tariot PN, Hamill RW. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1991;4: 48-51.
7. Bhattacharya KF, Giannakikou I, Munroe N, Chaudhuri KR. Primary anticholinergic-responsive Pisa syndrome. Mov Disord 2000;15: 1285-7.
8. Taylor P. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 1998;51(1 Suppl 1): S30-5. (Pubitemid 28345339)
9. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012;9: CD009132.
10. Huvent-Grelle D, Roche J, Camus FE, Dewailly P, Puisieux F. Relationship between cholinesterase inhibitors and Pisa syndrome in a cohort of five French patients with Alzheimer's disease. J Am Geriatr Soc 2007;55: 1472-5. (Pubitemid 47329227)
11. Kwak YT, Han IW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222. (Pubitemid 30394336)
12. Miyaoka T, Seno H, Yamamori C, et al. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry 2001;62: 573-4. (Pubitemid 32703103)
13. Villarejo A, Camacho A, García-Ramos R, et al. Cholinergicdopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol 2003;26: 119-21.
14. Cossu G, Melis M, Melis G, et al. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. Mov Disord 2004;19: 1243-4. (Pubitemid 39429972)
15. Chen CF, Hsu HC, Ouyang WC, Lin YC. Galantamineinduced pisa syndrome: memantine as an alternative. Int J Geriatr Psychiatry 2008;23: 660-1.
16. Shinfuku M, Nakajima S, Uchida H, Watanabe K, Kocha H, Kashima H. Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. Psychiatry Clin Neurosci 2011;65:299.
17. Leelavathi M, Rosdinom R, Suguna M. Pisa syndrome secondary to rivastigmine: a case report. Clin Ter 2012;163: 31-2.
18. Vanacore N, Suzzareddu G, Maggini M, Casula A, Capelli P, Raschetti R. Pisa syndrome in a cohort of Alzheimer's disease patients. Acta Neurol Scand 2005;111: 199-201. (Pubitemid 40278588)
19. Szarfman A, Tonning J, Doraiswamy PM. Pharmacovigilance in the 21st century: new tools for an old problem. Pharmacotherapy 2004;24: 1099-104. (Pubitemid 39128833)
20. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003;12: 559-74. (Pubitemid 37220642)
21. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82: 157-66. (Pubitemid 47078877)
22. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10: 483-6. (Pubitemid 34100774)
23. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11: 3-10. (Pubitemid 34269590)
24. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54: 315-21. (Pubitemid 28328016)
25. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-thanexpected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002;25: 381-92. (Pubitemid 34729136)
26. Pilette WL. Pisa syndrome, or pleurothotonus. Am J Psychiatry 1987;144: 969-70.